MONMOUTH JUNCTION, N.J.,
March 1, 2021 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical
care immunotherapy leader commercializing its blood purification
technology to treat deadly inflammation in critically-ill and
cardiac surgery patients around the world, will report fiscal
2020 financial results on Tuesday, March 9,
2021 at 4:45PM EST.
CytoSorbents Corporation to Report Q4 2020 and Fiscal 2020
Operating and Financial Results on Tuesday,
March 9, 2021
CytoSorbents' management will host a live conference call and
presentation webcast that will recount both operational and
financial progress during Q4 2020 and fiscal year ending
December 31, 2020 followed by a
question and answer session.
Conference Call Details:
Date: Tuesday, March 9, 2021
Time: 4:45 PM Eastern
Participant Dial-In: 201-389-0879
Conference ID: 13716351
Live Presentation Webcast:
http://public.viavid.com/index.php?id=143499
It is recommended that participants dial in approximately 10
minutes prior to the start of the call. There will also be a
simultaneous live webcast of the conference call that can be
accessed through the following audio feed
link: http://public.viavid.com/index.php?id=143499
http://public.viavid.com/index.php?id=108451http://public.viavid.com/index.php?id=105816An
archived recording and written transcript of the conference call
will be available under the Investor Relations section of the
Company's website at
http://cytosorbents.com/investor-relations/financial-results/
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 67 countries around the world, as an extracorporeal
cytokine adsorber designed to reduce the "cytokine storm" or
"cytokine release syndrome" that could otherwise cause massive
inflammation, organ failure and death in common critical illnesses.
These are conditions where the risk of death is extremely high, yet
no effective treatments exist. CytoSorb® is also being
used during and after cardiac surgery to remove inflammatory
mediators that can lead to post-operative complications, including
multiple organ failure. CytoSorb® has been used in more than
121,000 human treatments to date. CytoSorb has received
CE-Mark label expansions for the removal of bilirubin (liver
disease), myoglobin (trauma), and both ticagrelor and
rivaroxaban during cardiothoracic surgery. CytoSorb has
also received FDA Emergency Use Authorization in the United States for use in critically ill
COVID-19 patients with imminent or confirmed respiratory failure,
in defined circumstances. CytoSorb has also been granted FDA
Breakthrough Designation for the removal of ticagrelor in a
cardiopulmonary bypass circuit during emergent and urgent
cardiothoracic surgery.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding of more than $38 million from DARPA, the U.S. Department of
Health and Human Services (HHS), the National Institutes of Health
(NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S.
Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM),
Air Force Material Command (USAF/AFMC), and others. The Company has
numerous products under development based upon this unique blood
purification technology protected by many issued U.S. and
international patents and multiple applications pending, including
ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™,
VetResQ™, K+ontrol™, DrugSorb™, ContrastSorb, and
others. For more information, please visit the
Company's websites at www.cytosorbents.com and
www.cytosorb.com or follow us on Facebook and
Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 5, 2020, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us on Facebook and Twitter
Cytosorbents
Contact:
Amy Vogel
732-398-5394
avogel@cytosorbents.com
|
Public Relations
Contact:
Eric Kim
Rubenstein Public
Relations
212-805-3052
ekim@rubensteinpr.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cytosorbents-to-report-fiscal-2020-operating-and-financial-results-301237907.html
SOURCE CytoSorbents Corporation